INT152251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 16
Disease Relevance 6.15
Pain Relevance 3.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TMED4) endoplasmic reticulum (TMED4) signal transducer activity (TMED4)
Anatomy Link Frequency
uterus 1
MCF-7 1
band 1
fibroblast 1
TMED4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatosensory cortex 385 100.00 Very High Very High Very High
Bioavailability 4 99.18 Very High Very High Very High
primary somatosensory cortex 238 98.64 Very High Very High Very High
agonist 85 97.90 Very High Very High Very High
Inflammation 5 75.00 Quite High
Snapping jaw 1 75.00 Quite High
tetrodotoxin 16 74.48 Quite High
antagonist 36 73.76 Quite High
Pain 22 59.88 Quite High
Hippocampus 4 58.24 Quite High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 665 99.98 Very High Very High Very High
Breast Cancer 122 99.98 Very High Very High Very High
Cancer 88 99.86 Very High Very High Very High
Disease 1 97.24 Very High Very High Very High
Toxicity 9 96.12 Very High Very High Very High
Mental Disorders 14 94.60 High High
Temporomandibular Joint Disorders 2 92.04 High High
Endometriosis (extended) 22 90.56 High High
Metastasis 30 87.76 High High
Fibromyalgia 2 86.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The characteristic way that isoflavones bind to oestrogen receptors (ERs), mainly to beta-receptors (ERs-?)
Gene_expression (isoflavones) of ERs
1) Confidence 0.22 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.20 Pain Relevance 0
Bioavailability, metabolism, the ability to alter alpha-ERs distribution in the uterus and the estrogenic potential of parent compounds and metabolites may consequently contribute to the differences in “in vivo” estrogenicity of dietary flavonoids.
Gene_expression (distribution) of ERs in uterus associated with bioavailability
2) Confidence 0.19 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852849 Disease Relevance 0.13 Pain Relevance 0.10
PCR amplification and Western blotting were employed to target the expression of estrogen receptors (ERs) in human fibroblast-like synovial and ATDC5 cells.
Gene_expression (expression) of ERs in fibroblast
3) Confidence 0.15 Published 2008 Journal Int. J. Mol. Med. Section Abstract Doc Link 18506373 Disease Relevance 0.70 Pain Relevance 0.14
Irrespective of whether stimuli were randomly or predictably presented, the ADHD group showed substantive power decreases in SII alpha and beta ERD and SII beta rebound ERS relative to controls as well as a significantly shorter SII beta rebound.
Gene_expression (beta rebound) of ERS associated with somatosensory cortex and attention deficit hyperactivity disorder
4) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.60 Pain Relevance 0.75
It is the first to profile somatosensory ERS and ERD in ADHD and the first to show that beta rebound is not a uniform phenomenon but one that can be modified in the presence of a psychiatric disorder.
Gene_expression (profile) of ERS associated with mental disorders, somatosensory cortex and attention deficit hyperactivity disorder
5) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.72 Pain Relevance 0.20
Adults with ADHD also showed substantially less ERS than controls between 15 and 30 Hz in the latter half of the trial (1000+ ms) (also Figure 2D), indicating that individuals with ADHD experienced a significantly shorter beta rebound following a somatosensory event.
Gene_expression (showed) of ERS associated with attention deficit hyperactivity disorder
6) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.32 Pain Relevance 0.09
The TFR analysis of the ADHD group showed a strong early ERS in the lower bandwidths (theta and low alpha) and high beta band (25 to 40 Hz), but little power in the midrange (10 to 22 Hz) followed by ERD and a rebound ERS composed of strong activation during the first half of the rebound period and reduced activation in the latter half (Figure 3B).
Gene_expression (composed) of ERS in band associated with somatosensory cortex and attention deficit hyperactivity disorder
7) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.36 Pain Relevance 0.31
These group differences were substantiated in the permutation analyses which revealed that adults with ADHD displayed significantly less ERD and significantly shorter beta rebound ERS across both alpha and beta activities (Figure 5D).
Gene_expression (displayed) of ERS associated with somatosensory cortex and attention deficit hyperactivity disorder
8) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.33 Pain Relevance 0.35
These group differences were substantiated in the permutation analyses which revealed that adults with ADHD displayed significantly less ERD and significantly shorter beta rebound ERS across both alpha and beta activities (Figure 5D).
Gene_expression (beta rebound) of ERS associated with somatosensory cortex and attention deficit hyperactivity disorder
9) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.32 Pain Relevance 0.34
In the control group, SII exhibited strong early ERS from 5 Hz to 25 Hz followed by ERD and beta rebound ERS, consistent with the control Random SII response.
Gene_expression (response) of ERS associated with somatosensory cortex
10) Confidence 0.03 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2266931 Disease Relevance 0.30 Pain Relevance 0.67
The presence of functional ERs in MCF-7 cells exposed to ibandronate suggests that these cells should remain sensitive to antiestrogenic agents.
Gene_expression (presence) of ERs in MCF-7
11) Confidence 0.02 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0.32 Pain Relevance 0.03
The triphenylethylene antiestrogen tamoxifen is the classic hormonal treatment for the management of breast cancers expressing ERs [22].
Gene_expression (expressing) of ERs associated with breast cancer
12) Confidence 0.02 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 1.08 Pain Relevance 0.07
Moreover, the growth inhibition induced by classic antiestrogens, such as 4-hydroxytamoxifen and ICI 182,780, is larger on cancer cells expressing ERs when they are combined with ibandronate.
Gene_expression (expressing) of ERs associated with cancer
13) Confidence 0.02 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0.35 Pain Relevance 0
transcripts and proteins have been reported in GT1-1 cells [37], [63], it has been difficult to detect estrogen responses in these cells, probably due to low expression levels of ERs.
Gene_expression (expression) of ERs
14) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2910705 Disease Relevance 0.09 Pain Relevance 0.03
These results indicate that these cells are a potential cell based system to study the action of estrogens if they express ERs.
Gene_expression (express) of ERs
15) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2910705 Disease Relevance 0 Pain Relevance 0.34
Tamoxifen is a triphenylethylene antiestrogen with partial ER agonist activity and has been used for a couple of decades for the classic hormonal treatment of breast cancers expressing ERs [14,15].
Gene_expression (expressing) of ERs associated with breast cancer and agonist
16) Confidence 0.01 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0.33 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox